FR2669346B1 - Vaccin a poxvirus recombinant contre le virus de la rougeole. - Google Patents

Vaccin a poxvirus recombinant contre le virus de la rougeole.

Info

Publication number
FR2669346B1
FR2669346B1 FR9114256A FR9114256A FR2669346B1 FR 2669346 B1 FR2669346 B1 FR 2669346B1 FR 9114256 A FR9114256 A FR 9114256A FR 9114256 A FR9114256 A FR 9114256A FR 2669346 B1 FR2669346 B1 FR 2669346B1
Authority
FR
France
Prior art keywords
meals
vaccine against
recombinant poxvirus
poxvirus vaccine
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9114256A
Other languages
English (en)
French (fr)
Other versions
FR2669346A1 (fr
Inventor
Paoletti Enzo
Taylor Jill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virogenetics Corp
Original Assignee
Virogenetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virogenetics Corp filed Critical Virogenetics Corp
Publication of FR2669346A1 publication Critical patent/FR2669346A1/fr
Application granted granted Critical
Publication of FR2669346B1 publication Critical patent/FR2669346B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR9114256A 1990-11-20 1991-11-19 Vaccin a poxvirus recombinant contre le virus de la rougeole. Expired - Lifetime FR2669346B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62161490A 1990-11-20 1990-11-20
US77686791A 1991-10-22 1991-10-22

Publications (2)

Publication Number Publication Date
FR2669346A1 FR2669346A1 (fr) 1992-05-22
FR2669346B1 true FR2669346B1 (fr) 1995-07-21

Family

ID=27089007

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9114256A Expired - Lifetime FR2669346B1 (fr) 1990-11-20 1991-11-19 Vaccin a poxvirus recombinant contre le virus de la rougeole.

Country Status (12)

Country Link
JP (2) JP3617668B2 (enExample)
AU (1) AU1253892A (enExample)
BE (1) BE1005908A5 (enExample)
CA (1) CA2096633A1 (enExample)
CH (1) CH683921A5 (enExample)
DE (2) DE4192786B4 (enExample)
FR (1) FR2669346B1 (enExample)
GB (2) GB2283021B (enExample)
IE (2) IE68404B1 (enExample)
IT (1) IT1252687B (enExample)
NL (2) NL195058C (enExample)
WO (1) WO1992008789A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US6248333B1 (en) 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5756102A (en) * 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5989561A (en) * 1991-03-07 1999-11-23 Virogenetics Corporation Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses
EP0575491B1 (en) * 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
AU674491B2 (en) * 1991-03-20 1997-01-02 Virogenetics Corporation Recombinant poxvirus malaria vaccine
DE69233080T2 (de) * 1991-06-14 2004-04-15 Connaught Technology Corp., Greenville Rekombinanter hiv-spezifischer impfstoff aus poxviru
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
CN1089370C (zh) * 1994-12-08 2002-08-21 中国预防医学科学研究院病毒学研究所 表达麻疹病毒l4株血凝素及融合蛋白基因的重组痘苗病毒
AU2118997A (en) * 1996-02-05 1997-08-22 Johns Hopkins University, The Measles immunization by dna transcription unit inoculation
WO1998050047A1 (en) 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
EP1095948A1 (en) * 1999-10-28 2001-05-02 Universitätsklinikum Freiburg Idiotype vaccines
CN100446812C (zh) * 2001-03-08 2008-12-31 美国国有健康与人类服务部 表达修饰的hiv包膜、gag和pol基因的mva
AR052743A1 (es) * 2006-04-11 2007-03-28 Inst Nac De Tecnologia Agropec Vector plasmidico de transferencia y virus canarypox recombinante

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2617715B1 (fr) * 1987-07-07 1990-08-31 Transgene Sa Vecteur viral et adn recombinant codant pour une ou des proteines de surface (ha et/ou f) d'un morbillivirus, culture cellulaire infectee, proteines obtenues, vaccin et anticorps obtenus
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
FR2632863B2 (fr) * 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
JPH01218590A (ja) * 1988-02-29 1989-08-31 Toa Nenryo Kogyo Kk 組換ワクチニアウイルスを用いたリンダペスト（牛疫）ウイルスワクチン

Also Published As

Publication number Publication date
DE4192786B4 (de) 2006-08-24
NL195095C (nl) 2004-01-21
FR2669346A1 (fr) 1992-05-22
GB2283021A (en) 1995-04-26
ITMI913092A0 (it) 1991-11-20
NL9120026A (nl) 1993-09-01
NL195058C (nl) 2003-07-01
GB9500214D0 (en) 1995-03-01
DE4192786T1 (de) 1994-01-13
ITMI913092A1 (it) 1993-05-20
JPH06502996A (ja) 1994-04-07
AU1253892A (en) 1992-06-11
IE71643B1 (en) 1997-02-26
CH683921A5 (fr) 1994-06-15
IE913960A1 (en) 1992-05-20
GB9309414D0 (en) 1993-07-14
NL9900036A (nl) 2003-10-01
BE1005908A5 (fr) 1994-03-08
IT1252687B (it) 1995-06-23
WO1992008789A1 (en) 1992-05-29
JP3824619B2 (ja) 2006-09-20
GB2264949A (en) 1993-09-15
IE68404B1 (en) 1996-06-12
CA2096633A1 (en) 1992-05-21
GB2264949B (en) 1995-07-05
JP2005040129A (ja) 2005-02-17
JP3617668B2 (ja) 2005-02-09
GB2283021B (en) 1995-07-05

Similar Documents

Publication Publication Date Title
FI931309L (fi) Viralt bristfaelligt vaccin, som har producerats med en transkomplementerande cellinie
GB2246784B (en) Herpes virus recombinant poxvirus vaccine
ATE120489T1 (de) Rekombinante coccidiosis-vakzine.
LU91327I2 (fr) Vaccin papillomavirus humain Ätypes 56,11,16,18Ü(recombinant, adsorbé)
CY2007016I2 (el) Εμβολιο ιου θηλωματος
FR2629717B1 (fr) Preparation de vaccin
EP0621339A3 (en) Immunogenic human influenza a virus haemagglutinin polypeptides.
DE3853088D1 (de) Rekombinantes Avipoxvirus.
DE3850019D1 (de) Rekombinantes Avipoxvirus.
DZ1706A1 (fr) Vaccin contre le virus de l'hepatite a.
DE69230627D1 (de) Rekombinantes Avipoxvirus
EP0597016A4 (en) Infectious bursal disease virus recombinant poxvirus vaccine.
ZA924150B (en) Vaccine for human immunodeficiency virus
GB2264949B (en) Measles virus recombinant poxvirus vaccine
FI934725A7 (fi) Lastentauteihin tarkoitettu yhdistelmärokote, jonka kunkin rokotekomponentin immunogeenisyys on lisääntynyt
ZA964679B (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
DE68914043D1 (de) Coccidiosis-Vakzin.
NL300112I2 (nl) Vaccin tegen dermatomycosis.
AU6358190A (en) Polypeptide vaccines against foot-and-mouth disease virus
FI934777A0 (fi) Multipel hepatitis b virus ytproteiner som bildar partiklar
DE69020848D1 (de) Impfstoff gegen IBV.
DE68918189D1 (de) Neisseria-Vakzine.
EP0537232A4 (en) Recombinant pigeon pox virus vaccine
HU9203976D0 (en) Vaccine based on modified herpes virus
FI914673L (fi) Peptider, som reagerar immunokemiskt med antikroppar mot hepatitis icke-a, icke-b-virus.